NZ602126A - Ophthalmic Solution for Treating Ocular Infection Comprising Levofloxacin or Salt Thereof or Solvate of the Same, Method for Treating Ocular Infection, Levofloxacin or Salt Thereof or Solvate of the Same, and Use Thereof - Google Patents
Ophthalmic Solution for Treating Ocular Infection Comprising Levofloxacin or Salt Thereof or Solvate of the Same, Method for Treating Ocular Infection, Levofloxacin or Salt Thereof or Solvate of the Same, and Use ThereofInfo
- Publication number
- NZ602126A NZ602126A NZ602126A NZ60212610A NZ602126A NZ 602126 A NZ602126 A NZ 602126A NZ 602126 A NZ602126 A NZ 602126A NZ 60212610 A NZ60212610 A NZ 60212610A NZ 602126 A NZ602126 A NZ 602126A
- Authority
- NZ
- New Zealand
- Prior art keywords
- levofloxacin
- ophthalmic solution
- solvate
- salt
- same
- Prior art date
Links
- 208000001860 Eye Infections Diseases 0.000 title abstract 6
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 title abstract 6
- 229960003376 levofloxacin Drugs 0.000 title abstract 6
- 229940054534 ophthalmic solution Drugs 0.000 title abstract 4
- 239000002997 ophthalmic solution Substances 0.000 title abstract 4
- 150000003839 salts Chemical class 0.000 title abstract 4
- 239000012453 solvate Substances 0.000 title abstract 4
- 229940114474 levofloxacin ophthalmic solution Drugs 0.000 abstract 4
- 241000894006 Bacteria Species 0.000 abstract 3
- 241000191967 Staphylococcus aureus Species 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 201000007032 bacterial conjunctivitis Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 238000004904 shortening Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010040281 | 2010-02-25 | ||
| PCT/JP2010/072685 WO2011104981A1 (ja) | 2010-02-25 | 2010-12-16 | レボフロキサシンもしくはその塩またはそれらの溶媒和物を含有する眼感染症治療用点眼剤、眼感染症の治療方法、レボフロキサシンもしくはその塩またはそれらの溶媒和物、ならびにその使用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ602126A true NZ602126A (en) | 2013-10-25 |
Family
ID=44506417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ602126A NZ602126A (en) | 2010-02-25 | 2010-12-16 | Ophthalmic Solution for Treating Ocular Infection Comprising Levofloxacin or Salt Thereof or Solvate of the Same, Method for Treating Ocular Infection, Levofloxacin or Salt Thereof or Solvate of the Same, and Use Thereof |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20120316158A1 (enExample) |
| EP (1) | EP2540299B1 (enExample) |
| JP (3) | JP5600056B2 (enExample) |
| KR (2) | KR20130043611A (enExample) |
| CN (1) | CN102770141A (enExample) |
| BR (1) | BR112012021247A2 (enExample) |
| CA (1) | CA2791190C (enExample) |
| EA (1) | EA201290827A1 (enExample) |
| ES (1) | ES2568647T3 (enExample) |
| MX (1) | MX349603B (enExample) |
| MY (1) | MY183483A (enExample) |
| NZ (1) | NZ602126A (enExample) |
| PH (2) | PH12012501674A1 (enExample) |
| SG (1) | SG183427A1 (enExample) |
| TW (1) | TWI488627B (enExample) |
| WO (1) | WO2011104981A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2791190C (en) * | 2010-02-25 | 2017-12-12 | Santen Pharmaceutical Co., Ltd. | Ophthalmic solution for treating ocular infection comprising levofloxacin or salt thereof or solvate of the same, method for treating ocular infection, levofloxacin or salt thereof or solvate of the same, and use thereof |
| CN103550144B (zh) * | 2013-10-25 | 2015-10-14 | 深圳朗欧医药集团有限公司 | 盐酸左氧氟沙星组合物注射液及其制备方法 |
| JP6363833B2 (ja) * | 2013-11-22 | 2018-07-25 | ナノシータ株式会社 | 薄膜状高分子構造体 |
| CN104606198A (zh) * | 2015-01-09 | 2015-05-13 | 周元铎 | 盐酸左氧氟沙星在制备防治家蚕细菌性败血病药中的应用 |
| IT201900005280A1 (it) * | 2019-04-05 | 2020-10-05 | Ntc S R L | Composizione otologica |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3038722B2 (ja) | 1989-06-23 | 2000-05-08 | 日本電気株式会社 | 接合型電界効果トランジスタ |
| JP3192290B2 (ja) | 1993-08-04 | 2001-07-23 | カネボウ株式会社 | ポリエステル製耐熱ボトル |
| US7629458B2 (en) * | 2001-10-03 | 2009-12-08 | Teva Pharmaceutical Industries Ltd. | Preparation of levofloxacin and hemihydrate thereof |
| US7169792B2 (en) * | 2001-11-30 | 2007-01-30 | Lg Life Sciences Ltd. | Method of treating bacterial infections using gemifloxacin or a salt thereof and a β-lactam antibiotic |
| WO2005000307A1 (en) * | 2003-06-26 | 2005-01-06 | Santen Pharmaceutical Co., Ltd. | Ophthalmic composition containing quinolones and method of use |
| US20050009836A1 (en) | 2003-06-26 | 2005-01-13 | Laskar Paul A. | Ophthalmic composition containing quinolones and method of use |
| JP2009526003A (ja) * | 2006-02-10 | 2009-07-16 | パーリ・ファルマ・ゲーエムベーハー | 吸入療法用噴霧状抗生物質 |
| WO2008005276A2 (en) * | 2006-06-30 | 2008-01-10 | Directcontact Llc | Growth factor delivery system containing antimicrobial agents |
| EP2143422A1 (en) * | 2008-07-11 | 2010-01-13 | S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. | Ophthalmic compositions containing gemifloxacin for the treatment of ocular infections |
| CA2791190C (en) * | 2010-02-25 | 2017-12-12 | Santen Pharmaceutical Co., Ltd. | Ophthalmic solution for treating ocular infection comprising levofloxacin or salt thereof or solvate of the same, method for treating ocular infection, levofloxacin or salt thereof or solvate of the same, and use thereof |
-
2010
- 2010-12-16 CA CA2791190A patent/CA2791190C/en not_active Expired - Fee Related
- 2010-12-16 KR KR1020127024069A patent/KR20130043611A/ko not_active Ceased
- 2010-12-16 EP EP10846644.2A patent/EP2540299B1/en not_active Not-in-force
- 2010-12-16 KR KR1020177015979A patent/KR20170070265A/ko not_active Ceased
- 2010-12-16 PH PH1/2012/501674A patent/PH12012501674A1/en unknown
- 2010-12-16 JP JP2010280325A patent/JP5600056B2/ja active Active
- 2010-12-16 WO PCT/JP2010/072685 patent/WO2011104981A1/ja not_active Ceased
- 2010-12-16 MX MX2012009844A patent/MX349603B/es active IP Right Grant
- 2010-12-16 MY MYPI2012003769A patent/MY183483A/en unknown
- 2010-12-16 US US13/580,931 patent/US20120316158A1/en not_active Abandoned
- 2010-12-16 SG SG2012061842A patent/SG183427A1/en unknown
- 2010-12-16 ES ES10846644.2T patent/ES2568647T3/es active Active
- 2010-12-16 NZ NZ602126A patent/NZ602126A/xx not_active IP Right Cessation
- 2010-12-16 BR BR112012021247-8A patent/BR112012021247A2/pt not_active Application Discontinuation
- 2010-12-16 CN CN2010800646540A patent/CN102770141A/zh active Pending
- 2010-12-16 PH PH1/2016/501747A patent/PH12016501747B1/en unknown
- 2010-12-16 EA EA201290827A patent/EA201290827A1/ru unknown
- 2010-12-28 TW TW099146206A patent/TWI488627B/zh not_active IP Right Cessation
-
2012
- 2012-03-12 JP JP2012054761A patent/JP2012162532A/ja active Pending
-
2013
- 2013-08-16 JP JP2013169146A patent/JP5674882B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PH12012501674A1 (en) | 2012-11-05 |
| PH12016501747A1 (en) | 2019-02-11 |
| WO2011104981A1 (ja) | 2011-09-01 |
| US20120316158A1 (en) | 2012-12-13 |
| SG183427A1 (en) | 2012-09-27 |
| JP5600056B2 (ja) | 2014-10-01 |
| JP2013241464A (ja) | 2013-12-05 |
| EP2540299A4 (en) | 2013-07-24 |
| MX349603B (es) | 2017-08-03 |
| PH12016501747B1 (en) | 2022-06-22 |
| CA2791190C (en) | 2017-12-12 |
| JP5674882B2 (ja) | 2015-02-25 |
| JP2011195564A (ja) | 2011-10-06 |
| EP2540299A1 (en) | 2013-01-02 |
| BR112012021247A2 (pt) | 2018-04-03 |
| CN102770141A (zh) | 2012-11-07 |
| MY183483A (en) | 2021-02-20 |
| CA2791190A1 (en) | 2011-09-01 |
| AU2010346703A1 (en) | 2012-09-20 |
| JP2012162532A (ja) | 2012-08-30 |
| EP2540299B1 (en) | 2016-04-13 |
| TW201129364A (en) | 2011-09-01 |
| HK1177887A1 (en) | 2013-08-30 |
| EA201290827A1 (ru) | 2013-03-29 |
| KR20130043611A (ko) | 2013-04-30 |
| TWI488627B (zh) | 2015-06-21 |
| KR20170070265A (ko) | 2017-06-21 |
| ES2568647T3 (es) | 2016-05-03 |
| MX2012009844A (es) | 2012-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021550931A1 (en) | New anthelmintic compounds | |
| PH12019502851A1 (en) | New azaquinoline derivatives | |
| MX2020001403A (es) | Nuevos derivados de quinolina. | |
| MY195002A (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
| MX395482B (es) | Compuestos antiproliferativos y metodos de uso de los mismos | |
| MX2021011563A (es) | Derivados de 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmaceuticas que los incluyen. | |
| NZ751197A (en) | Compounds and methods of treating infections | |
| MX2018005041A (es) | Compuestos para tratar la esclerosis lateral amiotrofica. | |
| MX2017012545A (es) | Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas. | |
| MX2017017171A (es) | Compuestos terapeuticos y composiciones para el tratamiento de trastornos sociales y trastornos de uso de sustancias. | |
| EP4324454A3 (en) | Cross-linking agents and associated methods | |
| NZ702087A (en) | Pharmaceutical compositions and treatment of mastitis | |
| MX2020006309A (es) | Fórmulaciones de parasiticida de isoxazolina y métodos para el tratamiento de la blefaritis. | |
| EA201790726A1 (ru) | Фармацевтическая композиция для лечения язвенного колита | |
| PH12020551117A1 (en) | Compositions for preventing or treating uveitis | |
| MX2019011908A (es) | Macrociclos de peptidos anti-bacterianos y uso de los mismos. | |
| BR112019005456A2 (pt) | composição farmacêutica e método para tratamento de esteatose hepática não alcoólica | |
| GB2541840A (en) | Ophthalmic composition for the treatment of ocular infection | |
| MY183483A (en) | Ophthalmic solution for treating ocular infection comprising levofloxacin or salt thereof or solvate of the same, method for treating ocular infection, levofloxacin or salt thereof or solvate of the same, and use thereof | |
| MX2019006942A (es) | Agonistas de receptores de oxitocina no peptidicos. | |
| MY198195A (en) | Composition For Suppressing Or Improving Eye Fatigue | |
| MX2022006229A (es) | Composiciones y metodos para el tratamiento de resistencia a la insulina. | |
| PH12019502510A1 (en) | Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof | |
| MX2017012539A (es) | Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas. | |
| PH12020550549A1 (en) | Compositions for preventing or treating lupus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 16 DEC 2017 BY HENRY HUGHES IP LIMITED Effective date: 20140814 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 DEC 2018 BY CPA GLOBAL Effective date: 20171102 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 DEC 2019 BY CPA GLOBAL Effective date: 20181102 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 DEC 2020 BY CPA GLOBAL Effective date: 20191031 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 DEC 2021 BY CPA GLOBAL Effective date: 20201030 |
|
| LAPS | Patent lapsed |